WOBURN, Mass., Jan. 4, 2024 /PRNewswire/ -- Cytrellis Biosystems, a pioneer in novel medical aesthetic solutions and manufacturer of ellacor® and its proprietary Micro-Coring® Technology, announced today that Jason Richey, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 11, 2024, at 8:30 a.m. PST.
Event: 42nd Annual J.P. Morgan Healthcare Conference
Location: San Francisco, CA
When: January 11, 2024 at 8:30 a.m. PST
About ellacor®
The ellacor® system with Micro-Coring® technology is the first-and-only non-surgical procedure to remove sagging skin on the micro-scale. This pioneering system targets moderate and severe wrinkles in the mid and lower face, setting new standards in skin revitalization. Utilizing the groundbreaking, patented Micro-Coring® technology, the ellacor® system precisely removes full thickness cores of dermal and epidermal tissue with a 22 gauge (410 microns) hollow needle without thermal energy. The needle's minimal diameter minimizes any potential scarring risk, prioritizing patient safety and satisfaction. Indicated for use by qualified medical professionals, the ellacor® system with Micro-Coring® technology is designed for adults aged 22 years or older, encompassing Fitzpatrick skin types I-IV. For more information visit ellacor.com.
About Cytrellis Biosystems
Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices. Cytrellis' first product, ellacor® system with Micro-Coring technology, is a novel, proprietary system that removes sagging skin to address moderate and severe wrinkles. Ellacor® provides aesthetic practitioners with an unprecedented ability to improve age-related changes in skin to help restore youthful beauty.
Contacts:
Media:
EvolveMKD
Cytrellis@EvolveMKD.com
Investor Relations:
Jackson McAdam
Chief Financial Officer
JMcAdam@cytrellis.com
SOURCE Cytrellis